In this segment from Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass look at the recent earnings report from biotech company Celgene (NASDAQ:CELG), to sift out the vital numbers that investors need to know.

The guys note that while the top line for Celgene came in a little light, the company did beat on bottom line estimates. Despite phenomenal sales growth numbers for key drugs Revlimid, Abraxane, and Pomalyst, David also mentions that this may be an unfortunate case of the market's expecting even more from a star performer. David also discusses the company's deal with Nogra Pharma for the development and marketing of an experimental Crohn's disease drug, and looks ahead to one crucial court date for Revlimid that could be a huge blow to Celgene if the court decision doesn't go in the company's favor.

David Williamson and Michael Douglass have no position in any stocks mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.